Top News
FDA seeks external guidance on pathogen-agnostic sequencing framework for future outbreak detection and responseAgency consulting advisors on rapid diagnostic tools to identify novel pathogens without prior sequence knowledge, addressing gaps exposed by COVID-19.
UK updates gene therapy legal definition to include synthetic DNA and CRISPR editing, first revision since 2007Regulatory change modernizes Advanced Therapy Medicinal Products framework while maintaining compliance continuity with existing principles.
FDA rejects Capricor Therapeutics' cell therapy for Duchenne muscular dystrophySetback for the small-cap biotech's lead program; company had faced previous regulatory challenges on the asset.
- Sanofi in talks to acquire Insmed for ~$43B as Dupixent patent exclusivity nears expiration
Deal would diversify Sanofi's pipeline beyond blockbuster Dupixent as generic competition looms; Insmed shares surged 20% on news.
Innogen licenses China-approved GLP-1 efsubaglutide alfa to Arcera for $1B+ in four-region dealAbu Dhabi's Arcera Life Sciences gains rights to Diabegone (efsubaglutide alfa), expanding access to Innogen's metabolic therapy beyond China.
More: Pharmaceutical Executive
- Experimental pancreatic cancer drug halts tumor growth in 90% of patients in early-stage trial.
Small trial shows promise for new mechanism; researchers exploring extension to other cancer types.
Compass and Usona race toward first FDA-approved psychedelic drug as commercial viability hinge on pricing and payer coverageBoth companies pursuing psychiatric indications; reimbursement landscape remains uncertain for emerging psychedelic medicine category.
More: PharmaVoice
Alterome releases early Phase 1 data for selective KRAS inhibitor targeting pancreatic, lung, and colorectal cancersPreliminary results show activity across multiple KRAS-driven tumor types; full efficacy and safety profile unclear pending detailed readout.
EMA grants orphan drug designation to Enterprise Therapeutics' novel cystic fibrosis therapyOrphan designation accelerates development pathway and provides regulatory incentives including market exclusivity for rare respiratory disease treatment.
Two new drugs for hepatitis B and herpes gain US approval in October; 2026 year-to-date approvals total 429October approvals of 35 drugs down 39% from September; full-year pace tracking fourth-highest in BioWorld's historical records.
- Hikma raises 2026 profit guidance; executive sells £1.1M in shares
Director's stock sale comes as pharma group signals improved financial outlook for full-year results.
- Biointron's RushDATA platform enables antibody candidates from sequence design to validation data in five days using cell-free and CHO systems
Platform accelerates validation bottleneck as generative AI speeds sequence design; positions rapid iteration as competitive advantage in discovery pipelines.
Japan grants world's first conditional approvals for iPSC products: Cuorips' Riheart and Sumitomo/Racthera's AmchepryNobel-winning induced pluripotent stem cell technology enters commercial market in Japan.
Major pharma companies to halt clinical trials at select Chinese hospitals amid regulatory or geopolitical pressureMove affects trial operations at unspecified hospitals; details on scope, timeline, and affected programs not yet disclosed.
China adds 107 drugs to 2026 reimbursement lists, including record 51 Class I innovative medicinesLists take effect January 1, 2027; dual-track system expands access to breakthrough therapies.
- AbbVie partners with Disco Pharmaceuticals in $2.54B collaboration to develop bispecific therapies for solid tumors
Deal leverages Disco's cell surface mapping technology to identify new cancer targets with high unmet medical need.
More: BioWorld, BioWorld, Pharmaceutical Executive
FDA approves Sanofi's Infilbray (venglustat), oral glucosylceramide synthase inhibitor, for type 3 Gaucher diseaseFirst oral GCS inhibitor approval in this indication; Sanofi sees new revenue stream as Dupixent patent cliff approaches.
More: BioPharma Dive, BioWorld
US panel warns China could dominate biopharmaceutical sector; calls for urgent legislation to curb American biotech investment in China.Novartis CEO says restrictions risk slowing drug development; commission fears supply chain vulnerability and overdependence.
More: Bloomberg — Technology
- Recursion secures FDA alignment on novel Phase III endpoint for FAP therapy; study initiation targeted for 2027
AI-driven biotech advances fibrillosis program with agency-agreed efficacy measure, moving toward pivotal trial launch.
FDA approves Regeneron's Livsayis (cemdisiran), first siRNA therapy for generalized myasthenia gravisRegeneron's C5-directed siRNA will compete against AstraZeneca and Argenx in autoimmune disease market.
More: BioPharma Dive, Pharmaceutical Executive, Pharmaceutical Technology
FDA accepts IND for Evotec-BMS cereblon E3 ligase modulator from protein degradation partnershipSecond CELMoD from BMS collaboration enters Phase I next year, expanding molecular glue pipeline in immunology.
Vitrivax closes $87M Series C to advance Lyme disease vaccine candidates into clinical trialsThermostable antigen platform ALTA enables room-temperature storage, addressing cold-chain barriers in vaccine deployment.
Gates Foundation expands Akagera Medicines TB mRNA vaccine grant by $7.8M for LNP dendritic cell targetingCumulative grant now supports clinical-stage dendritic cell-targeted mRNA platform, addressing major infectious disease burden.
- Novartis leans on multi-billion-dollar pipeline readouts to offset patent cliff and growth headwinds
CEO addresses investor concerns at annual management day as company faces wave of near-term exclusivity losses.
More: Pharmaceutical Executive
- FDA proposes withdrawing approval of Salerno's Flolipid (simvastatin) suspension for failure to file annual NDA reports
Tulsa-based company has repeatedly missed required filings; withdrawal would remove liquid statin formulation from US market.